# Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

> **NCT03149848** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 15 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** Cabotegravir
- **DRUG:** Rifabutin

## Key facts

- **NCT ID:** NCT03149848
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-06
- **Primary completion:** 2017-09-06
- **Final completion:** 2017-09-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149848, "Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03149848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*